145 related articles for article (PubMed ID: 35914785)
21. Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study.
Faller G; Mistry BJ; Tikly M
Pediatr Rheumatol Online J; 2014 Jan; 12():2. PubMed ID: 24397895
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients.
Mathiesen PR; Zak M; Herlin T; Nielsen SM
Clin Exp Rheumatol; 2010; 28(5):782-9. PubMed ID: 21029565
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes in Juvenile Myositis patients.
Tsaltskan V; Aldous A; Serafi S; Yakovleva A; Sami H; Mamyrova G; Targoff IN; Schiffenbauer A; Miller FW; Simmens SJ; Curiel R; Jones OY; Rider LG
Semin Arthritis Rheum; 2020 Feb; 50(1):149-155. PubMed ID: 31303436
[TBL] [Abstract][Full Text] [Related]
24. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
Sanner H; Sjaastad I; Flatø B
Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
Almeida B; Campanilho-Marques R; Arnold K; Pilkington CA; Wedderburn LR; Nistala K;
Arthritis Rheumatol; 2015 Sep; 67(9):2495-502. PubMed ID: 25988361
[TBL] [Abstract][Full Text] [Related]
26. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
Orandi AB; Dharnidharka VR; Al-Hammadi N; Baszis KW;
Pediatr Rheumatol Online J; 2018 Dec; 16(1):84. PubMed ID: 30594206
[TBL] [Abstract][Full Text] [Related]
27. Juvenile dermatomyositis: extramuscular manifestations and their management.
Lowry CA; Pilkington CA
Curr Opin Rheumatol; 2009 Nov; 21(6):575-80. PubMed ID: 19730375
[TBL] [Abstract][Full Text] [Related]
28. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
Phillippi K; Hoeltzel M; Byun Robinson A; Kim S;
J Pediatr; 2017 May; 184():38-44.e1. PubMed ID: 28410093
[TBL] [Abstract][Full Text] [Related]
29. Using imaging methods to assess severe calcinosis in juvenile dermatomyositis: A case report.
Xu H; Wang L; Wei S; Li C; Yuan K
Int J Rheum Dis; 2023 Mar; 26(3):554-558. PubMed ID: 36539990
[TBL] [Abstract][Full Text] [Related]
30. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
31. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops.
Smith RL; Sundberg J; Shamiyah E; Dyer A; Pachman LM
J Rheumatol; 2004 Aug; 31(8):1644-9. PubMed ID: 15290747
[TBL] [Abstract][Full Text] [Related]
32. Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
Neely J; Long CS; Sturrock H; Kim S;
Arthritis Care Res (Hoboken); 2019 Dec; 71(12):1600-1605. PubMed ID: 30714338
[TBL] [Abstract][Full Text] [Related]
33. [Multi-center analysis of calcinosis in children with juvenile dermatomyositis].
Miyamae T; Mori M; Inamo Y; Kohno Y; Takei S; Maeda M; Murata T; Nakata S; Kawai H; Hirano Y; Date Y; Kitamura K; Yokota S
Ryumachi; 2003 Jun; 43(3):538-43. PubMed ID: 12910962
[TBL] [Abstract][Full Text] [Related]
34. Decreased capillary density in juvenile dermatomyositis and in mixed connective tissue disease.
Scheja A; Elborgh R; Wildt M
J Rheumatol; 1999 Jun; 26(6):1377-81. PubMed ID: 10381059
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
Marco Puche A; Calvo Penades I; Lopez Montesinos B
Clin Exp Rheumatol; 2010; 28(1):135-40. PubMed ID: 20346254
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Calcinosis in Juvenile Dermatomyositis.
Kul Cinar O; Papadopoulou C; Pilkington CA
Curr Rheumatol Rep; 2021 Feb; 23(2):13. PubMed ID: 33555459
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the biomarkers related to the clinical course and outcomes of juvenile dermatomyositis.
Lin TW; Hu YC; Chiang BL
J Microbiol Immunol Infect; 2023 Apr; 56(2):416-423. PubMed ID: 36572597
[TBL] [Abstract][Full Text] [Related]
38. Initial manifestations and risk factors for calcinosis in juvenile dermatomyositis: A retrospective multicenter study.
Cakan M; Ozdel S; Karadag SG; Ulu K; Cakmak F; Yener GO; Ozturk K; Baglan E; Sonmez HE; Demir F; Sozeri B; Ayaz NA
North Clin Istanb; 2023; 10(3):298-305. PubMed ID: 37435297
[TBL] [Abstract][Full Text] [Related]
39. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
[TBL] [Abstract][Full Text] [Related]
40. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature.
Sener S; Basaran O; Batu ED; Sag E; Oz S; Talim B; Bilginer Y; Haliloglu G; Ozen S
Semin Arthritis Rheum; 2023 Feb; 58():152133. PubMed ID: 36434896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
